Relief Therapeutics Holding AG
RLFTF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $8,417 | $6,033 | $6,081 | $3,321 |
| % Growth | 39.5% | -0.8% | 83.1% | – |
| Cost of Goods Sold | $2,575 | $1,736 | $1,250 | $750 |
| Gross Profit | $5,842 | $4,297 | $4,831 | $2,571 |
| % Margin | 69.4% | 71.2% | 79.4% | 77.4% |
| R&D Expenses | $1,357 | $1,328 | $12,922 | $19,024 |
| G&A Expenses | $9,242 | $17,229 | $20,745 | $15,871 |
| SG&A Expenses | $9,830 | $19,429 | $24,052 | $16,236 |
| Sales & Mktg Exp. | $588 | $2,200 | $3,307 | $365 |
| Other Operating Expenses | $13,540 | $94,368 | $19,897 | $1,617 |
| Operating Expenses | $24,727 | $115,125 | $56,871 | $36,877 |
| Operating Income | -$18,885 | -$110,828 | -$52,040 | -$34,306 |
| % Margin | -224.4% | -1,837% | -855.8% | -1,033% |
| Other Income/Exp. Net | -$471 | -$856 | -$2,276 | -$1,219 |
| Pre-Tax Income | -$19,356 | -$111,684 | -$54,316 | -$35,525 |
| Tax Expense | -$2,237 | -$13,503 | -$3,526 | -$820 |
| Net Income | -$17,119 | -$98,181 | -$50,790 | -$34,705 |
| % Margin | -203.4% | -1,627.4% | -835.2% | -1,045% |
| EPS | -1.37 | -8.35 | -4.8 | -3.86 |
| % Growth | 83.6% | -74% | -24.4% | – |
| EPS Diluted | -1.37 | -8.35 | -4.8 | -3.86 |
| Weighted Avg Shares Out | 12,540 | 11,752 | 10,570 | 8,983 |
| Weighted Avg Shares Out Dil | 12,540 | 11,752 | 10,570 | 8,983 |
| Supplemental Information | – | – | – | – |
| Interest Income | $188 | $396 | $18 | $0 |
| Interest Expense | $215 | $330 | $156 | $797 |
| Depreciation & Amortization | $2,561 | $3,318 | $3,860 | $2,036 |
| EBITDA | -$16,580 | -$108,036 | -$49,022 | -$32,692 |
| % Margin | -197% | -1,790.8% | -806.2% | -984.4% |